Abstract
BackgroundAdalimumab (ADA) has been shown to be safe and effective in polyarticular juvenile idiopathic arthritis (pJIA), and is approved for use in moderate to severe pJIA patients (pts) ≥4 years...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have